Biogen Inc. announced on Tuesday a definitive agreement to acquire Apellis Pharmaceuticals, Inc. in an all-cash transaction valued at roughly $5.6 billion. Under the terms, Apellis shareholders will receive $41.00 per share in cash at closing, alongside a non-transferable contingent value right (CVR) that could yield up to an additional $4.00 per share if certain annual global net sales targets for Syfovre are achieved.
Strategic Rationale and Market Context
The acquisition arrives at a pivotal moment for both companies. Biogen is actively seeking new growth engines as its core multiple sclerosis franchise faces increasing competitive and pricing pressures. Apellis, meanwhile, brings two commercial rare disease therapies that generated $689 million in net product revenue during 2025 and are projected to grow at a mid-to-high teens percentage rate through 2028.
Apellis's portfolio is anchored by Syfovre (pegcetacoplan), the first approved treatment for geographic atrophy (GA), a severe form of age-related macular degeneration that leads to irreversible vision loss. Syfovre captured approximately 60% of the U.S. GA market in 2025, with revenue of $587 million and injection volumes growing 17% year-over-year. The company also markets Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and two rare kidney disorders, which contributed $102 million in revenue last year.
Financial and Operational Details
The $41.00 per share cash consideration represents an approximate 86% premium over Apellis's 90-day volume-weighted average price and a roughly 140% premium over its closing price on Monday, March 30, 2026. Following the announcement, Apellis stock surged to $40.32 in early trading, while Biogen shares saw a slight decline to $178.25.
Beyond the immediate products, the transaction provides Biogen with an established U.S. nephrology commercial infrastructure. This asset is strategically timed, as Biogen anticipates Phase 3 data for its own kidney disease candidate, felzartamab, in the first half of 2027. Analysts viewed the move positively; Barclays' Emily Field described it as a "signal of confidence" ahead of those key clinical readouts, while RBC Capital Markets' Brian Abrahams suggested it could offer a "much-needed near-term boost to earnings."
Leadership Commentary and Scientific Synergy
Biogen's Chief Executive Officer, Christopher Viehbacher, framed the acquisition as a component of the company's "ongoing transformation" strategy. Apellis CEO Cedric Francois stated the combination would "accelerate our impact" for patients. Apellis's pipeline is focused on targeting the complement system, a critical part of the innate immune response, offering Biogen an expanded footprint in complement-driven diseases within nephrology and rare disorders.
Apellis also aims to file for regulatory approval of a prefilled syringe for Syfovre in the first half of 2026, which could improve administration convenience.
Risks and Forward Path
The deal is not without its challenges. Syfovre competes with Astellas Pharma's Izervay in the GA market and carries label warnings for risks of retinal vasculitis and retinal vascular occlusion—inflammatory events or blockages in the eye's blood vessels. Clinical trials also indicated an increased rate of wet age-related macular degeneration. The acquisition remains subject to customary closing conditions, including regulatory approvals and the successful completion of a tender offer for Apellis shares. The companies are targeting a close in the second quarter of 2026.
Biogen expects the transaction to be accretive to its adjusted earnings per share beginning in 2027. The company plans to provide updated financial guidance for the full year 2026 when it reports first-quarter earnings. This strategic bet on the complement space represents a significant step for Biogen as it navigates a post-blockbuster era for its historic core business.
